Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (391-400 of 621) with videos related to

Pageof 63
Sort By:
JAMA Oncology|December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical TrialManish A Shah, Yung-Jue Bang, Florian Lordick, et al.
Health Technology Assessment (Winchester, England)|February 4, 2014
The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluationEmma Loveman, Jeremy Jones, Andrew J Clegg, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Histopathology|February 22, 2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trialNasser Davarzani, Gordon G A Hutchins, Nicholas P West, et al.
Journal of Interventional Cardiology|December 31, 2013
Do outcomes from transcatheter aortic valve implantation vary according to access route and valve type? The UK TAVI RegistryDaniel J Blackman, Paul D Baxter, Chris P Gale, et al.
Pancreas|December 20, 2019
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 TrialTeresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, et al.
Rare Tumors|January 26, 2023
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymomaPreethika Mahalingam, Sam Smith, Juanita Lopez, et al.
Journal of the National Cancer Institute|June 25, 2014
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trialFrancesco Sclafani, David Gonzalez, David Cunningham, et al.
World Journal of Surgery|March 10, 2022
Impact of the COVID-19 Pandemic on Pediatric Surgical Volume in Four Low- and Middle-Income Country Hospitals: Insights from an Interrupted Time Series AnalysisPaul Park, Ruth Laverde, Greg Klazura, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Pageof 63

Showing results (391-400 of 621) with videos related to

Sort By:
Pageof 63
JAMA Oncology|December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical TrialManish A Shah, Yung-Jue Bang, Florian Lordick, et al.
Health Technology Assessment (Winchester, England)|February 4, 2014
The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluationEmma Loveman, Jeremy Jones, Andrew J Clegg, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Histopathology|February 22, 2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trialNasser Davarzani, Gordon G A Hutchins, Nicholas P West, et al.
Journal of Interventional Cardiology|December 31, 2013
Do outcomes from transcatheter aortic valve implantation vary according to access route and valve type? The UK TAVI RegistryDaniel J Blackman, Paul D Baxter, Chris P Gale, et al.
Pancreas|December 20, 2019
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 TrialTeresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, et al.
Rare Tumors|January 26, 2023
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymomaPreethika Mahalingam, Sam Smith, Juanita Lopez, et al.
Journal of the National Cancer Institute|June 25, 2014
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trialFrancesco Sclafani, David Gonzalez, David Cunningham, et al.
World Journal of Surgery|March 10, 2022
Impact of the COVID-19 Pandemic on Pediatric Surgical Volume in Four Low- and Middle-Income Country Hospitals: Insights from an Interrupted Time Series AnalysisPaul Park, Ruth Laverde, Greg Klazura, et al.
British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.
Pageof 63